Citigroup Other Income (Expense) increased by 22.5% to $359.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 336.2%, from -$152.00M to $359.00M. Over 2 years (FY 2021 to FY 2024), Other Income (Expense) shows a downward trend with a -22.2% CAGR.
An increase suggests higher non-operating gains or lower non-operating costs, while a decrease indicates higher non-operating expenses or lower non-operating income.
Represents the net total of non-operating financial activities, including interest income, interest expense, foreign cur...
Standard across all public companies; peers in the medical device sector often show similar volatility due to currency fluctuations.
other_income_expense_net| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $451.00M | $31.00M | $398.00M | $201.00M | -$174.00M | $300.00M | -$348.00M | $913.00M | -$92.00M | $178.00M | $477.00M | $62.00M | -$51.00M | $218.00M | -$152.00M | -$884.00M | $293.00M | $359.00M |
| QoQ Change | — | -93.1% | >999% | -49.5% | -186.6% | +272.4% | -216.0% | +362.4% | -110.1% | +293.5% | +168.0% | -87.0% | -182.3% | +527.5% | -169.7% | -481.6% | +133.1% | +22.5% |
| YoY Change | — | — | — | — | -138.6% | +867.7% | -187.4% | +354.2% | +47.1% | -40.7% | -47.8% | +167.4% | -128.7% | — | -131.9% | <-999% | +674.5% | +336.2% |